651 results
CORRESP
BMY
Bristol-Myers Squibb Co.
9 Sep 13
Correspondence with SEC
12:00am
of the related products, describe the nature of the asset for which the payment is made. If these payments are not for an asset (i.e. based on sales), tell us … on the nature of the arrangement, including its contractual terms, the nature of the payments and the applicable accounting guidance. The most common activities
CORRESP
BMY
Bristol-Myers Squibb Co.
29 Jun 10
Correspondence with SEC
12:00am
by the end of 2010. Please disclose the nature of the efficiencies and the amount of reductions in expenses by line item in 2009. Please also disclose … the nature of the efficiencies and the estimated amount of these reductions in expenses by line item for 2010, 2011, 2012.
Mr. Jim B. Rosenberg
Page 2
CORRESP
BMY
Bristol-Myers Squibb Co.
18 Jan 22
Correspondence with SEC
12:00am
are inherently recurring in nature. Please explain the factors that you considered in concluding that exclusion of these charges complied with Question … , such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of future
CORRESP
BMY
Bristol-Myers Squibb Co.
4 Nov 13
Correspondence with SEC
12:00am
to a collaborative arrangement based on the nature of the arrangement, the nature of its business operations, the contractual terms of the arrangement … the need to evaluate the nature of the payments between the parties to the arrangement. We believe this further supports our view that such payments
CORRESP
BMY
Bristol-Myers Squibb Co.
7 Jan 14
Correspondence with SEC
12:00am
; or if there is no appropriate analogy, a reasonable, rational, consistently applied accounting policy election after considering the specific nature … of the arrangement, including its contractual terms, the nature of the payments and the applicable accounting guidance.
Our collaboration partners
8-K
EX-1
79b7il9hprymf6b
27 Nov 06
As representatives of the several Managers
12:00am
CORRESP
odbnxxzpgyhjdlm12s
17 May 12
Correspondence with SEC
12:00am
8-K
EX-1.1
gj57n9 ehcl7xd0z
31 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-1.1
hrdz mitj54do3zy
7 May 08
Nordic Capital Fund Vii and Avista Capital Partners Agree to Acquire Convatec Business for Approximately $4.1 Billion
12:00am
8-K
EX-1.1
jigrmu35fl31ib8toff
31 Oct 13
Other Events
12:00am
8-K
piqzu9
11 Aug 05
Entry into a Material Definitive Agreement
12:00am
SC TO-T/A
EX-99
40sn1 h4ivmxmzuvy7jp
23 Jul 12
Third party tender offer statement (amended)
12:00am
8-K
EX-10.3
49g1p0n17o
4 May 21
Departure of Directors or Certain Officers
4:16pm